Co-Diagnostics Inc (CODX): Average Forecast Price

Co-Diagnostics, Inc. (CODX) specializes in developing high-precision diagnostic systems for medicine. This price chart illustrates the impact of stringent FDA standards and unique patents on the issuer's market position, where the indicator stands at 3.99. Management, led by Dwight Egan, aims to bring a home PCR analyzer to the mass market. Simultaneously, the business is implementing ESG principles through bio-waste recycling and eco-friendly packaging.

CODX (Co-Diagnostics Inc) Consensus Target history from 07/04/2022 to 11/11/2026

Analytical breakdowns for Co-Diagnostics Corp (CODX)

- market price and analyst price targets:

Stock Quotes codiagnostics.com|CODX - Price Target Chart

- stock exchange capitalization data:

Market Value Co-Diagnostics Corp|CODX - Enterprise Value

- shareholders' equity book value data:

Equity per Share Co-Diagnostics|CODX - Company Net Assets|Capitalization to Book Value Ratio codiagnostics.com|CODX - Aggregate Company Assets

- debt obligations and liquidity statistics:

- net income and valuation multiples indicators:

CODX - Net Profit|Projected Future Earnings Co-Diagnostics, Inc.|CODX - Price to Earnings Ratio|Future Price to Earnings Co-Diagnostics Inc|CODX - Price/Earnings to Growth Multiple|Company Value to EBITDA Co-Diagnostics Corp|CODX - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Co-Diagnostics|CODX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months codiagnostics.com|CODX - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Co-Diagnostics, Inc.

General company analysis:codiagnostics.com (CODX)

This indicator measures the arithmetic mean of target prices from leading investment banks, allowing investors to distinguish a temporary correction from a fundamental degradation of the business. The trend of the aggregate market consensus target reflects a revision of the fair value of Co-Diagnostics, Inc. (CODX), where the diversification of diagnostic systems and expansion into European and US markets serve as key factors stabilizing analyst forecasts.

Competing companies